William J. Gradishar, MD, Northwestern University Feinberg School of Medicine, shares his expert insights on the evolving treatment landscape for HER2-positive metastatic breast cancer. In this discussion, he explores the potential impact of DESTINY-Breast09 and the combination of trastuzumab deruxtecan (T-DXd) with pertuzumab as a first-line option, comparing it to the long-standing THP regimen. Dr. Gradishar also weighs in on sequencing strategies, the role of antibody-drug conjugates (ADCs), and the clinical importance of tailoring treatment based on toxicity profiles and patient-specific factors.
ASCO 2025: Focus on Treatment Sequencing in mBC
Stay up to date with the latest research and clinical updates on breast cancer treatment sequencing from the 2025 American Society of Clinical Oncology Annual Meeting.
Advertisement
Dr. Kelly McCann reviews sequencing and emerging therapies in HR-positive, HER2-negative metastatic breast cancer.
Dr. Kelly McCann of UCLA details HER2-positive breast cancer sequencing and toxicity management.
Dr. Kelly McCann discusses evolving treatment sequencing strategies in metastatic triple-negative breast cancer.
Dr. Gradishar discusses how tolerability, toxicity, and NCCN guidelines shape HER2+ breast cancer treatment decisions.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.